Adorx Therapeutics Limited
Registered name: ADORX THERAPEUTICS LIMITED
Part of Epidarex Management Ltd groupAdorx Therapeutics Limited made £1.2m revenue and £211k profit in the year to 28 Feb 2025. read from filing text
Adorx Therapeutics Limited’s revenue fell 91% to £1.2m in the year to 28 Feb 2025, with £211k profit and 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in Edinburgh; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- Edinburgh, Scotland
- Age
- 9 yrs · since 2017
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 28 Feb 2024 | 28 Feb 2025 |
|---|---|---|
| Disclosure | Full P&Lread from filing text | Full P&Lread from filing text |
| Profit & loss | ||
| Revenue (turnover) | £12.8m | £1.2m |
| Cost of sales | £732k | £1.1m |
| Gross profit | £12.1m | £140k |
| Operating profit | £11.9m | £27.3k |
| Profit before tax | £12m | £89.4k |
| Profit after tax | £13.1m | £211k |
| Profit (best available) | £13.1m | £211k |
| Staff costs | £53.2k | £53.4k |
| Employees (average) | — | 0 |
| Ratios | ||
| Profit margin | 102.7% | 17.6% |
| Gross margin | 94.3% | 11.7% |
| Cash conversion | −88.2% | −4989% |
| Growth (year on year) | ||
| Revenue growth | — | ▼90.6% |
| Profit growth | — | ▼98.4% |
| Balance sheet — indirect signals, not revenue | ||
| Cash at bank | £5.4m | £4.9m |
| Net assets | £7.8m | £4.9m |
| Current assets | £9.2m | £5m |
| Debtors | £2.6m | £0 |
| Deferred income | £1.2m | £0 |
| Cash from operations | −£10.5m | −£1.4m |
| Source | FullAccounts · bulk data Nov 2025 | FullAccounts · bulk data Nov 2025 |
How the business works
- Profit margin
- 17.6%
- Profit ÷ revenue.
- Gross margin
- 11.7%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- —
- Profit ÷ average employees.
- Cash conversion
- −4989%
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 0%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 0%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼38%
- Now £4.9m
- Cash at bank
- ▼10%
- Now £4.9m
- Headcount
- —
- Now 0
- Deferred income
- ▼100%
- Now £0
- Fixed assets
- —
- Now —
Group structure
Ownership chain
- Epidarex Management Ltdultimate parent75–100%
- Epidarex Capital Partners Limited50–75%
- Adorx Therapeutics Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (1)
- Clyde Biosciences LimitedFigures not disclosed
Minority corporate shareholders
- CRT Pioneer GP Limited 25–50%
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Nuritas UK LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £88.8k
- Staff
- 4
- Clinicology Ltd.Guildford · Research and experimental development on biotechnology
- Revenue
- £1.4m
- Profit
- £79.1k
- Staff
- 7
- Collaborative Community Against Coronavirus CICLondon · Research and experimental development on biotechnology
- Revenue
- £786k
- Profit
- £29.9k
- Staff
- 0
- Takara Bio UK LtdLondon · Research and experimental development on biotechnology
- Revenue
- £3.1m
- Profit
- £97.2k
- Staff
- 9
Sources
Latest figures from FullAccounts for the year to 28 Feb 2025 (profit £211k), from the Companies House accounts bulk data published Nov 2025. Spotted an error? Request a correction.
Updated from Companies House on 15 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.